Palonosetron oral

Drug Profile

Palonosetron oral

Alternative Names: Aloxi Capsule

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharma Europe; Helsinn; Roche; Sinclair IS Pharma
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 06 Mar 2015 No recent reports on development identified - Phase-III for Chemotherapy induced nausea and vomiting (Prevention) in India, Russia, Ukraine and Mexico (PO)
  • 17 Jul 2014 Oral palonosteron licensed to Chugai Pharma Europe in United Kingdom
  • 01 Oct 2012 Efficacy and adverse events data from a phase III trial in Chemotherapy induced nausea and vomiting presented at the Annual Congress of the European Society for Medical Oncology (ESMO-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top